Novo Nordisk and the Chinese Academy of Science (CAS) have signed an agreement that establishes a joint research foundation in China. The aim of Novo Nordisk–Chinese Academy of Science Research Foundation is to fund or co-fund activities of common interest within the fields of diabetes and biopharmaceuticals, including related disciplines and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology, endocrinology and drug delivery.
"We look forward to a fruitful cooperation with Novo Nordisk," says Professor Chen Zhu, CAS vice president and chair person of the Foundation. "Chinese and Danish scientists share a history of excellent collaborations which the new foundation will further strengthen. Novo Nordisk is well recognised in China for its major role in preventing and treating diabetes. We are very pleased to collaborate with Novo Nordisk and believe the collaboration will be of great benefit to both parties."
In January 2002, Novo Nordisk established a world class R&D centre in Beijing, which is the first R&D centre in China established by international bio-pharmaceutical companies. After five years of R&D activity in China, Novo Nordisk decided to cooperate with CAS and fund 2,000,000 US dollars in supporting research in diabetes and biopharmaceuticals.
"This cooperation illustrates the great attention Novo Nordisk pays to China as well as our long-term commitment to help in further developing the Chinese healthcare system," says Dr Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. He also emphasises that Novo Nordisk will continue to launch new products in China and increase the company’s R&D presence in the country
5 Mar 2007 :